In the Morf4l2 knockdown group, anti-PD1, BLZ945, and BLZ945 plus anti-PD1 partially suppressed tumor growth, whereas in the control group, BLZ945 plus anti-PD1 evidently suppressed tumor growth (Fig. 7A-D). The gene discussed is MORF4L2; the disease is neoplasm.